Return to Listing

5 result(s) for Urologic / Genitourinary Cancers

PI Name Protocol # Title
Christopher Ryan STUDY00016085 [NCI CIRB] A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Christopher Ryan STUDY00016300 A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Jacqueline Vuky STUDY00016506 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
Christopher Ryan STUDY00016576 A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
Christopher Ryan STUDY00017381 [NCI CIRB] A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NAÏVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080